For patients with ductal carcinoma in situ (DCIS), active monitoring (AM) is noninferior to guideline-concordant care (GCC) ...

Study reveals short term safety of active monitoring for ductal carcinoma in situ. ScienceDaily . Retrieved January 1, 2025 from www.sciencedaily.com / releases / 2024 / 12 / 241212115836.htm ...

F RIDAY, Dec. 13, 2024 (HealthDay News) -- For patients with ductal carcinoma in situ (DCIS), active monitoring (AM) is noninferior to guideline-concordant care (GCC) that involves surgery with or ...

Each year, more than 56,500 women are diagnosed with ductal carcinoma in situ (DCIS), a non-invasive type of breast cancer commonly referred to as Stage 0 breast cancer. A woman with DCIS is ...

A new study, published in the New England Journal of Medicine, examines whether removing lymph nodes is always necessary in ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Ibrance is under clinical development by Pfizer and currently in Phase III for Head And Neck Squamous Cell Carcinoma (HNSC).

SAN ANTONIO — For patients with so-called “good-risk” ductal carcinoma in situ (DCIS) who did not have radiation therapy after breast-conserving surgery, adjuvant tamoxifen reduced their ...

More information: Patient-Reported Outcomes for Low-Risk Ductal Carcinoma In Situ A Secondary Analysis of the COMET Randomized Clinical Trial, JAMA Oncology (2024). DOI: 10.1001/jamaoncol.2024. ...

Over the last decade, it has become widely accepted that there is indeed considerable overdiagnosis of both ductal carcinoma in situ and invasive breast cancer. As many as one in three breast ...

More information: Hwang ES, et al. Active Monitoring With or Without Endocrine Therapy for Low-Risk Ductal Carcinoma In Situ: The COMET Randomized Clinical Trial. JAMA (2024) DOI: 10.1001/jama ...